Compare TPR & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | DXCM |
|---|---|---|
| Founded | 1941 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 26.5B |
| IPO Year | 2000 | 2005 |
| Metric | TPR | DXCM |
|---|---|---|
| Price | $156.87 | $62.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $142.20 | $85.33 |
| AVG Volume (30 Days) | 1.4M | ★ 3.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 47.18 |
| EPS | ★ 3.93 | 2.09 |
| Revenue | ★ $5,880,000,000.00 | N/A |
| Revenue This Year | $12.39 | $14.46 |
| Revenue Next Year | $5.36 | $12.31 |
| P/E Ratio | $38.33 | ★ $29.32 |
| Revenue Growth | ★ 31.01 | N/A |
| 52 Week Low | $61.60 | $54.11 |
| 52 Week High | $161.97 | $89.07 |
| Indicator | TPR | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.37 | 40.83 |
| Support Level | $137.27 | $60.57 |
| Resistance Level | $160.13 | $69.18 |
| Average True Range (ATR) | 4.36 | 1.92 |
| MACD | 1.27 | 0.01 |
| Stochastic Oscillator | 92.81 | 32.71 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.